Prevalence of Adverse Drug Reactions of Anti-Hypertensive Drugs in A Tertiary Care Hospital, Bhairahawa, Nepal
DOI:
https://doi.org/10.3126/jcmsn.v18i4.51061Abstract
Introduction
Hypertension represents the common disease worldwide which mostly requires long-term therapy and combination of two or more antihypertensive drugs. These drugs are frequently linked to adverse drug reactions. The objective of the study was to determine the prevalence of adverse drug reactions in patients under anti-hypertensive drugs.
Methods
The study was a cross-sectional study conducted among 250 hypertensive patients under medications at the medicine department of Universal College of Medical Sciences- Teaching Hospital. Face-to-face interviews were used to gather the data, which was then recorded on an adverse medication reaction monitoring form. Naranjo algorithm scale was used to categorize the causality relationship of adverse drug reactions.
Results
Out of 250 hypertensive patients, a total of 73 ADR cases (29.2%) were observed. The most commonly linked drugs with ADRs were calcium channel blockers (65.8%) followed by ARBs (12.3%), Beta-blockers (9.6%) and Diuretics (6.8%). Amlodipine (62.9%) was found to be the most frequently linked drug to ADR. Most of the ADRs in the current study fell under category possible (38.3%) followed by definite (28.8%), probable (21.9%) and doubtful (11%) respectively.
Conclusions
Patients taking anti-hypertensive drugs commonly experience adverse drug reactions. The study recommends that ADR monitoring be conducted continually in hospital settings in order to identify and document any adverse effects brought on by various drugs so that it would be helpful for doctors to rationally prescribe.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Anjan Palikhey, Ramita Chaudhary, Laxmi Shrestha , Amit Kumar Shrivastava , Chandrajeet Kumar Yadav, Anish Giri, Ajit Kumar Sah, Jharana Shrestha
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.